Changes in LDL-C levels among primary health care patients with hypertension, coronary artery disease, and diabetes during a 36-month follow-up Authors: Petra Valkonen, Ulla Mikkonen, Hannu Kautiainen, Pekka Mäntyselkä, Nina Tusa Published: 2026 ABSTRACT AbstractBackground and aimsLow-density lipoprotein cholesterol (LDL-C) level is one important modifiable risk factor for cardiovascular diseases. This study aimed to describe the characteristics of primary health care patients with hypertension, coronary artery disease, or diabetes according to their LDL-C levels and to observe changes in these levels and medications during the 36-month follow-up.MethodsThis study was based on a clinical trial, conducted in a health centre in Siilinjärvi, Finland, between 2017 and 2021. A total of 507 patients with hypertension, coronary artery disease, or diabetes were divided into four groups based on their baseline LDL-C levels to align with the dyslipidaemia guideline risk categories as follows: LDL-C (mmol/L) in Group 0 (< 1.4), Group 1 (1.4–1.8), Group 2 (>1.8–2.6), and Group 3 (> 2.6).ResultsThe mean age at baseline was 69 years (58% females). All patients in Groups 0 and 1 already used lipid-lowering medication. A lower LDL-C level at baseline was statistically significantly associated with higher age, lower blood pressureand lower alcohol consumption. There were changes in the pharmacologically active substances prescribed in all groups. During the 36-month follow-up, the mean LDL-C values decreased statistically significantly in group 3 (−0.76 mmol/L, 95% CI −0.90 to −0.62, −21%, p < .001: [ANCOVA]). The highest increase in lipid-lowering medication prescriptions occurred within this group.ConclusionsThis study provides a perspective on real-word treatment patterns and changes in medications prescribed as the recommendations change over time. During a period of increasing pharmacotherapeutic opportunities, this study, conducted in everyday clinical practice suggests that common lipid-lowering medications (atorvastatin and rosuvastatin) are most frequently used for primary health care patients, and are associated with a significant decrease in LDL-C levels. A greater decrease was observed among patients with higher baseline LDL-C values. Despite decreases in LDL-C, this study suggests that the gap remains between guideline-recommended treatment targets and achieved LDL-C levels. Introduction Primary health care bears the main responsibility for identifying dyslipidaemia and supporting patients’ treatment adherence [1]. Atherosclerotic cardiovascular diseases (ASCVD) are the leading cause of death globally [2]. Dyslipidaemia is a condition in which the lipid profile of plasma is unfavourable, causing an increased risk of development of ASCVDs [3]. According to the Finnish Current Care Guidelines, dyslipidaemia is defined as having a plasma low-density lipoprotein cholesterol (LDL-C) concentration above 3 mmol/L, a plasma triglyceride above 1.7 mmol/L, or high-density lipoprotein cholesterol below 1.0 mmol/L in males or 1.2 mmol/L in females [1]. The most common form of dyslipidaemia is hypercholesterolaemia, which is mainly characterised by increased LDL-C [4], a major ASCVD risk factor that can be modified with appropriate treatment [3,5]. According to current guidelines, there are four different target LDL-C levels with lipid-lowering treatments that are based on the patient’s individual risk of developing ASCVD. The treatment target for LDL-C is < 1.4 mmol/L for particularly high-risk patients, < 1.8 mmol/L for high-risk patients, < 2.6 mmol/L for moderate risk patients, and < 3 mmol/L for the rest of the population (the low-risk patients). The treatment targets for LDL-C have progressively tightened as more research is conducted [1,3,6]. The European Atherosclerotic Society (EAS) and the European Society of Cardiology (ESC) state in their guideline for dyslipidaemia that timely, active secondary prevention in primary health care decreases morbidity [3,5]. The meta-analysis covering 170,000 patients showed a 10% decline in all-cause mortality per LDL-C reduction of 1.0 mmol/L [7]. Therefore, the treatment should be effective and incorporate both drug-free and medication-based approaches [1,3]. The medication-based options include different lipid-lowering medications (LLM), such as statins, ezetimibe, fibrates, bile acid sequestrants, and proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9-inhibitors). Statins are the first line LLM and are effective both in lowering LDL-C and reducing risk for ASCVD and thus overall-mortality [1,3,5,8]. There seems to be a clinically relevant gap in achieving recommended LDL-C level in general. The da Vinci study, a European-wide cohort study among primary and secondary care patients receiving LLM for primary or secondary prevention found that in 2016 more than half of the patients did not reach the LDL-C treatment target defined by the ESC/EAS [9]. Furthermore, in 2019, over two thirds of those patients did not meet the desired target [9]. When only the secondary prevention patients were selected from the data, the LDL-C level goal attainment was even more unsatisfactory with 80–90% of patients falling short of it in 2019 [9]. In the multinational observational SANTORINI study, another study among primary and secondary care patients at high or very high ASCVD risk receiving LLMs across Europe between 2020 and 2021, showed that 80% of high risk or very high-risk patients did not meet their LDL-C treatment targets [10]. In a 2020 Finnish study among primary health care patients with hypertension and an LDL-C target set below 3 mmol/L, a third of patients using LLM did not meet the treatment target [11]. Despite extensive research on lipid management in general, previous literature provides only little data on adherence to tighter LDL-C targets and LLM use in everyday clinical practice in primary health care. This study aimed to characterise primary health care patients with hypertension, diabetes, or coronary artery disease according to their LDL-C levels and to assess changes in these levels and LLM prescriptions over a 36-month follow-up. Methods The study This analysis is based on a randomised controlled study, Participatory Patient Care Planning in Primary Care (4PHC), conducted at the municipal health centre in Siilinjärvi, Finland, between 2017 and 2021 (ClinicalTrials.gov ID: NCT02992431). In the original study, the patients were randomised into the intervention (participatory care planning process) or usual care group. Based on previously published data on the trial, these two groups did not differ significantly in primary outcome (health-related quality of life or clinical outcomes) at 12 or 36 months [12,13]. Thus, in this study, all patients were analysed as one unified group. Inclusion criteria for the study included age ≥18 years and a physician-diagnosed hypertension (HA), coronary artery disease (CAD), and/or diabetes (DM) based on International Classification of Diseases, 10th Revision (ICD-10). The patients in the HA group did not have CAD or DM. The patients classified into the CAD group could also have HA, and the patients classified into the DM group could have either or both conditions in addition to diabetes. Patients in the terminal phase of any serious condition or in severe cognitive decline were excluded. At baseline, there were 605 patients in total. Of those, 507 were included in this study since they had LDL-C measurements both at baseline and 12 and/or 36 months. Outcomes Main outcome, fasting plasma concentration of LDL-C was collected and analysed in the laboratory of the Kuopio University hospital using common laboratory standards and methods. The patients were divided into four groups based on their baseline LDL-C levels to align with the guideline risk categories as follows: LDL-C under 1.4 mmol/L (Group 0), between 1.4 and 1.8 (Group 1), over 1.8 to 2.6 (Group 2), and over 2.6 (Group 3). Other measurements Glycated haemoglobin A1C (HbA1C) was measured at laboratory after a 12 h fast. A trained nurse measured both the systolic and diastolic blood pressure after 10 min of resting in a sitting position and height (cm) and weight (kg) in light clothing at baseline at the appointment. The body mass index (BMI) was calculated by dividing the weight (kg) by the height (m2) squared from measurements taken by the study nurse at baseline. Data on lipid-lowering medications were retrieved from nurse-verified medication list. Patients answered a questionnaire concerning sociodemographic factors such as educational background in years and relationship status. Patients’ self-reported additional long-term diseases were asked. Lifestyle factors such as smoking habits (yes or no) and alcohol consumption (the first 2 questions of AUDIT-C [14]) were determined. The level of physical activity was reviewed using the KASARI fit index (Frequency x Intensity x Time [15],) in which the results are scaled from 0 to 100, 100 being the most active. Statistical analyses Descriptive statistics were presented as means with standard deviation (SD) (continuous variables), as medians with interquartile range (IQR) (ordinal variables), or as counts with percentages. The unadjusted hypothesis of linearity across LDL-C levels was tested using the Cochran–Armitage test, linear-by-linear test (categorical variables), or analysis of variance (ANOVA) (continuous variables) with an appropriate contrast. Mean changes between the baseline and 36-month LDL-C measurements were assessed using analysis of variance or covariance (ANCOVA). A possible nonlinear relationship between LDL-C levels and use of LLMs was evaluated using a 3-knot restricted cubic spline logistic model (categorical variables). Normal distributions were evaluated graphically and with the Shapiro–Wilk W test. Stata 18 (StataCorp LP, College Station, TX, USA) were used for the analysis. Results As presented in Table 1, at baseline, 5% of patients had LDL-C < 1.4 mmol/L (Group 0), 14% had LDL-C between 1.4 and 1.8 mmol/L (Group 1), 41% had LDL-C between >1.8 and 2.6 mmol/L (Group 2), and 40% had LDL-C over 2.6 mmol/L (Group 3). As seen in Table 1, a lower LDL-C level at baseline was statistically significantly associated with higher age, lower blood pressure, lower alcohol consumption, and fewer self-reported additional long-term diseases. Table 1.Characteristics of the patients at baseline. Group 0LDL-C < 1.4N = 25Group 1LDL-C 1.4–1.8N = 73Group 2LDL-C > 1.8–2.6N = 207Group 3 LDL-C > 2.6N = 202p ValueDiagnosis, n (%) <.001a[ χ2] Hypertension4(16)14(19)71(34)122(60) Coronary artery disease9(36)20(27)40(19)17(8) Diabetes12(48)39(53)96(46)63(31) Female, n (%)9(36)35(48)109(53)114(56).42b[Cochran–Armitage χ2 test]Age, years, mean (SD)71(9)71(8)69(9)68(9).004b[ANCOVABody Mass Index (BMI), kg/m2, mean (SD)30.7(8.1)29.4(5.5)29.5(5.5)28.8(5.6).11b[ANCOVAWaist, cm, mean (SD) Women103(12)102(16)97(17)98(15).22b[ANCOVA Men105(12)102(11)105(11)104(13).87b[ANCOVALiving with a spouse, n (%)19(76)48(67)146(72)140(69).80b[Cochran–Armitage χ2 test]Education, years, mean (SD)9.4(2.9)10.6(3.2)10.0(3.0)10.2(3.1).64b[ANCOVASmoking, n (%)8(8)8(12)3(8)33(11).46b[Cochran–Armitage χ2 test]Alcohol dosages per week, median (IQR)0.4(0.0,1.0)0.4(0.0,1.0)0.8(0.0,1.8)0.8(0.4,1.8).046bPhysical activity, Kasari FIT index, mean (SD)47.8(21.9)41.5(17.8)40.7(20.8)41.9(19.2).51b[ANCOVABlood pressure, mmHg, mean (SD) Systolic144(15)143(17)145(17)148(19).051b[ANCOVA Diastolic79(10)77(10)82(10)84(11)<.001b[ANCOVAHbA1c, mmol/mol, mean (SD) [number]Patients with diabetes49(8) 8[12]44(8) [39]47(11) [96]44(10) [63].55bNumber of self-reported diseases <.001b[χ2 test, linear-by-linear test] 16 (24)6 (8)42 (20)59 (29) 2–37 (28)46 (63)124 (60)113 (56) >312 (48)21 (29)41 (20)30 (15) Note: LDL-C: low-density lipoprotein cholesterol; HbA1C: glycated haemoglobin A1c.ap Value between groups.bp Value for linearity of levels between groups. Characteristics of the patients at baseline. Note: LDL-C: low-density lipoprotein cholesterol; HbA1C: glycated haemoglobin A1c. ap Value between groups. bp Value for linearity of levels between groups. There was a relationship between LLMs and LDL-C levels (Figure 1). The relation was almost a U-shape: The highest use of LLMs was observed in patients with the lowest and highest LDL-C levels. Baseline low-density lipoprotein cholesterol (LDL-C) levels and the percentage of patients prescribed lipid-lowering medications (LLM). The solid line shows the relationship between LDL-C levels and use of LLMs, evaluated using a 3-knot restricted cubic spline logistic model with the grey area representing 95% confidence intervals. The dotted line shows the average medication use. The different shades of grey describe different LDL-C risk groups (0–3) used in the study. There was a linear trend in changes in LDL-C levels from baseline to 36 months; the largest decrease being −0.76 in Group 3 (−0.90 to − 0.62, p = .001, adjusted for baseline value) as seen in Table 2. Table 2.Baseline LDL-C levels and changes over 36 months by baseline groups. Low-density lipoprotein cholesterol at baselineP for linearity Group 0<1.4N = 25Group 11.4–1.8N = 73Group 2>1.8–2.6N = 207Group 3>2.6N = 202 Baseline1.17 (0.13)1.63 (0.13)2.22 (0.23)3.60 (0.70) After 36 months1.19 (0.26)1.58 (0.34)2.12 (0.65)2.84 (0.96) Change0.03 (−0.08 to 0.14)−0.05 (0.13 to 0.03)−0.10 (−0.19 to 0.01)−0.76 (−0.90 to −0.62)0.015* [0.010 baseline adjusted]Percentage change % (95 % CI)2 (−2 2 to 27)−3 (−16 to 9)−5 (−10 to 0)−21 (−24 to −19) *p = .010 after adjustment for baseline value. Baseline LDL-C levels and changes over 36 months by baseline groups. p = .010 after adjustment for baseline value. Table 3 shows the amount of LLMs prescribed at baseline and at 36 months. At baseline the most commonly prescribed LLM was simvastatin and at 36 months rosuvastatin. At baseline, all patients in Groups 0 and 1 already had prescriptions for LLM. In Group 2 and 3, the percentage of patients prescribed with LLM increased during the 36-month follow-up, with the greatest increase seen in Group 3. Of the patients not using LLM at baseline, 36 (39%) were prescribed LLM during follow-up. Of the patients prescribed with LLM at baseline, 37 (12.3%) did not use LLM after 36 months. Table 3.Percentages of different pharmacologically active substances prescribed, their median dosages, and the percentage of patients with prescriptions, per group at baseline and after 36 months. Medications prescribed per group (%) Group 0LDL-C < 1.4Group 1LDL-C 1.4–1.8Group 2LDL-C > 1.8–2.6Group 3LDL-C > 2.6Median dose (mg/day)ATCa / pharmacologically active substanceBaseline36 moBaseline36 moBaseline36 moBaseline36 moBaseline36 moC10AA01 simvastatin32.028.042.535.632.923.77.95.42020C10AA05 atorvastatin16.016.028.824.732.935.313.421.32020C10AA07 rosuvastatin44.040.020.527.411.618.47.921.81010C10AX09 ezetimibe8.08.05.56.84.38.75.99.91010C10AA03 pravastatin0.00.01.41.41.00.53.02.04030C10AA04 fluvastatin0.00.01.44.11.91.00.51.08080C10AC01 colestyramine0.00.01.41.40.50.00.50.0600400C10BA01 lovastatin and nicotinic acid0.00.00.00.01.00.51.00.530b30bC10BA02 simvastatin and ezetimibe0.00.00.00.00.50.00.50.030/100C10AB02 bezafibrate0.00,00.00.00.00.00.50.04000C10AB04 gemfibrozil0.00.00.00.00.00.00.50.5600600C10BX11 atorvastatin. amlodipine and perindopril0.00.00.01.40.00.00.00.5015cC10AX13 evolocumab0.00.00.00.00.00.00.00.50140C10AX14 alirocumab0.00.00.00.00.00.00.00.50150Medications prescribed per group (%)100.092.0100.0100.086.587.941.663.9 a ATC = Anatomical Therapeutic Chemical.bDosage refers to lovastatin. c Dosage refers to atorvastatin. Percentages of different pharmacologically active substances prescribed, their median dosages, and the percentage of patients with prescriptions, per group at baseline and after 36 months. ATC = Anatomical Therapeutic Chemical. bDosage refers to lovastatin. Dosage refers to atorvastatin. Discussion This study described the changes in low-density lipoprotein cholesterol levels and lipid-lowering medication prescribed over 36 months among primary health care patients with hypertension, coronary artery disease, or diabetes. The LDL-C levels declined statistically significantly during the study period amongst the patients with the highest LDL-C levels at baseline. Regarding LLMs, our results propose that LDL-C levels below 1.8 or 1.4 mmol/L seem to be possible to achieve with statin therapy alone, which is the golden standard for dyslipidaemia treatment. Despite the evidence of reduced mortality with treatment of hypercholesterolaemia, the treatment targets are rarely achieved [3,9–11,16,17]. CAD and DM patients are at high or very high risk for ASCVD related complications and terminal events. Thus, their individual LDL-C target level is at least below 1.8 or even 1,4 mmol/L. When using this interpretation, 73% of patients in our study in baseline fell short of this presumed target, which is in line with previously referred studies. The Da Vinci study concluded that 80–90% of secondary prevention patients did not meet the desired target in 2019 [9]. Among hypertension patients, one third failed to meet their targets in the Finnish study of 2020 [11]. Still, lowering LDL-C level by just 1 mmol/L can reduce all-cause mortality [3,7,18]. In our study, the majority of patients received statin only, as monotherapy. The most significant change in the LLMs prescribed was a tendency towards switching from simvastatin to rosuvastatin or atorvastatin. The first recommended LLM to be combined with a statin is ezetimibe [1,3,5], but less than 10% of patients in our study were prescribed it at 36 months. In addition, one option for enhancing lipid-lowering treatment is to increase the statin dosage. Our data shows that the three most prescribed statins are being used in low dosages. Only a few patients were prescribed the newer PCSK9-inhibitors. The Finnish Institute of Health and Welfare provides bi-annually updated national statistics on CAD and DM patients’ LDL-C levels. That data shows a uniform decline in LDL-C levels towards lower values in both CAD and DM patients of all ages [19,20]. One factor influencing our results may be the mid-study update and tightening of treatment targets [1,3]. This indicates that the tightened treatment targets had been put into use. It would be interesting to follow up on whether a longer observation period after the updated and tightened recommendations would affect the treatment and LDL-C levels of our patients. Several factors should be considered when aiming to achieve successful treatment with LLM. We observed that patients near the LDL-C value of 3 were less likely to be prescribed with LLM. This might be due to clinical inertia or patients’ own decision [16,21–23]. Maintaining compliance with prescribed long-term medications is a worldwide issue recognised by the World Health Organization [24]. LLMs lower LDL-C more effectively if taken regularly [25]. Dyslipidaemia is also an asymptomatic condition which may affect adherence to effective care [26]. In the twenty first century, the media has familiarised the public with side effects of statins which leads to poorer medication adherence [23,27]. The negative attitude towards the use of statins, which may lead to discontinuation of medication, has been associated with an increased risk of cardiovascular complications [23]. Interestingly, continuity of care has been linked to statins being prescribed more often, as well as better adherence to statin treatment [28–30]. Providing patients with adequate explanations of the importance of LDL-C, ASCVD risk reduction and LLM may enhance medication adherence [23,31,32]. Motivational interview intervention has been linked to better outcomes in medication adherence [33]. These insights regarding LLM should be acknowledged in clinical care. Strengths and limitations There are some limitations and strengths that should be taken into consideration. On the one hand, not knowing the individual target levels for each patient is a limitation in this study. For the same reason, we could not provide data at 36 months on how many patients had achieved their personalised treatment goal. Thus, we were only able to illustrate this issue through baseline LDL-C risk levels. Another limitation is that we do not know whether the patients used the medications prescribed. The source of the LLM information was the existing nurse-verified medication list, yet that does not tell us what the medication adherence in real life was. On the other hand, a strength of the study is that the patients were selected from the general flow of patients in primary health care with common illnesses. Thus, the study mirrors the study question in everyday clinical practice. The dropout rates remained quite low over the 36 months period, and the observation period is relatively long, which are strengths of the study. In the present study, we combined the two original arms of the randomised controlled trial. We considered that justified because no statistically significant difference in primary outcomes (including LDL-C) was found by the non-targeted participatory care plans of the original study design. Conclusion This study provides a perspective on real-word treatment patterns and changes in medications prescribed as the recommendations change over time. During increasing pharmacotherapeutic opportunities, this study suggests that common lipid-lowering medications are associated with decreasing or maintaining lower LDL-C levels among primary health care patients with chronic ASCVDs. Patients who were achieving the lowest LDL-C levels were prescribed either simvastatin, atorvastatin, or rosuvastatin and/or ezetimibe. The more lipid-lowering medications are prescribed, the more likely it is to achieve lower LDL-C level. A greater decrease was observed among patients with higher baseline LDL-C values. Despite the achieved decrease in LDL-C, this study, conducted in everyday clinical practice suggests that the gap remains between guideline-recommended treatment targets and achieved LDL-C levels despite the availability of pharmacological opportunities to enhance treatment.